Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.

about

Analysis of Postprandial Glycemia in Relation to Metabolic Compensation and Other Observed Parameters of Outpatients with Type 2 Diabetes Mellitus in the Czech Republic.Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients

P2860

Q49824036-206C6558-315F-474E-B5F2-82D491C6ED4B Q58585434-402B9A11-FF39-4D55-B2C1-CA9A9D98928B

P2860

Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q39101008

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rationale for treatment option ...... patients with type 2 diabetes.

@en

Rationale for treatment option ...... patients with type 2 diabetes.

@nl

type

Item

label

Rationale for treatment option ...... patients with type 2 diabetes.

@en

Rationale for treatment option ...... patients with type 2 diabetes.

@nl

prefLabel

Rationale for treatment option ...... patients with type 2 diabetes.

@en

Rationale for treatment option ...... patients with type 2 diabetes.

@nl

P1476

Rationale for treatment option ...... patients with type 2 diabetes.

@en

P2093

Stephen L Aronoff

http://www.w3.org/2001/XMLSchema#string

P2860

Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Meglitinide analogues in the treatment of type 2 diabetes mellitus.

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication.

P304

231-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1285191

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28118069

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.

about

P2860

P2860

Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921